Colossal Biosciences, a leader in de-extinction and species preservation, has secured an additional $200 million in Series C funding, led by TWG Global. The company uses advanced technologies in AI, genetic engineering, and computational biology to pursue its goal of reviving extinct species such as the thylacine, dodo, and woolly mammoth.
TWG Global Backs Colossal Biosciences with High-Profile Investors
Founded by Mark Walter, CEO of Guggenheim Partners, and Thomas Tull, former CEO of Legendary Entertainment, TWG Global is renowned for its significant investments and involvement in entertainment projects. Walter emphasized Colossal’s leadership in the emerging field of de-extinction and species conservation, praising its world-class team and technological innovations.
Colossal has attracted prominent investors from diverse industries, extending beyond its ambitious scientific goals. Notable Hollywood figures like Oscar-winning filmmakers Peter Jackson and Fran Walsh (known for Lord of the Rings), along with tech and finance leaders such as former Amazon executive Jeff Wilke, video game pioneer Richard Garriott, and billionaires Paul Tudor Jones and Robert Nelsen, have supported the company.
Colossal Biosciences Secures $435 Million to Advance De-Extinction and Biotechnology
With the latest funding, Colossal’s total investment reaches $435 million, bringing its valuation to $10.2 billion. The company intends to use this new capital to further enhance its genetic engineering technologies and develop innovative software, wetware, and hardware solutions that will not only advance de-extinction but also contribute to species preservation and human healthcare.
Colossal’s work has attracted significant attention for its potential to revolutionize both conservation and biotechnology. The company’s efforts could provide ground-breaking solutions for reviving extinct species, protecting those near extinctions like the northern white rhinoceros, and offering applications that extend beyond conservation into other fields.
Summary:
Colossal Biosciences has raised $200 million in Series C funding, bringing its total investment to $435 million with a valuation of $10.2 billion. Backed by high-profile investors from Hollywood, tech, and finance, the company is advancing de-extinction and species preservation through cutting-edge technologies in genetic engineering, AI, and biotechnology.
